Indications
Xerava is indicated in adolescents from the age of 12 years weighing at least 50 kg, and in adults, for the treatment of complicated intra-abdominal infections (cIAI). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Composition
- Active substance
- eravacycline
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Xerava
- Active substance
- eravacycline
- ATC code
- J01AA13
- Therapeutic area
- Infection, Bacterial Infections
- Marketing authorisation holder
- PAION Pharma GmbH
- Status